<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Long-term survivors of acquired <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> (AA) have an increased risk of developing <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) and <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) after immunosuppressive therapy (IST) </plain></SENT>
<SENT sid="1" pm="."><plain>It is uncertain whether the increased survival time simply discloses the natural history of AA as a premalignant disease or whether <z:e sem="disease" ids="C0277555" disease_type="Disease or Syndrome" abbrv="">secondary disease</z:e> is related to the therapy itself </plain></SENT>
<SENT sid="2" pm="."><plain>Between November 1992 and September 1997, 113 AA children with <z:mpath ids='MPATH_458'>normal</z:mpath> cytogenetics at diagnosis were treated with IST using antithymocyte globulin, cyclosporin, and <z:chebi fb="1" ids="4315">danazol</z:chebi> with or without granulocyte colony-stimulating factor (G-CSF) </plain></SENT>
<SENT sid="3" pm="."><plain>We assessed risk factors for developing <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> by Cox proportional hazards models </plain></SENT>
<SENT sid="4" pm="."><plain>Twelve of 113 patients developed <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> between 9 and 81 months following the time of diagnosis, giving a cumulative incidence of 13.7 +/- 3.9% </plain></SENT>
<SENT sid="5" pm="."><plain>The following cytogenetic abnormalities were observed at the time of diagnosis of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>: <z:mp ids='MP_0004026'>monosomy</z:mp> 7 (6 patients), monosomy7/<z:e sem="disease" ids="C0013080" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">trisomy21</z:e> (1 patient), <z:mp ids='MP_0004027'>trisomy</z:mp> 11 (1 patient), del (11) (9?:14) (1 patient), add (9q) (1 patient), add 7 (q 32) (1 patient), and <z:mp ids='MP_0004027'>trisomy</z:mp> 9 (1 patient) </plain></SENT>
<SENT sid="6" pm="."><plain>The number of days of G-CSF therapy and nonresponse to therapy at 6 months were statistically significant risk factors by multivariate analysis </plain></SENT>
<SENT sid="7" pm="."><plain>The present study suggests a close relationship between long-term use of G-CSF and <z:e sem="disease" ids="C0280745" disease_type="Neoplastic Process" abbrv="">secondary MDS</z:e> in nonresponders to IST </plain></SENT>
</text></document>